Science News

from research organizations

Simple “gut reset” may stop weight gain after Ozempic or Wegovy

A simple outpatient procedure could help prevent the common weight regain seen after stopping Ozempic or semaglutide.

Date:

April 23, 2026

Source:

Digestive Disease Week

Summary:

A new minimally invasive procedure may help people keep weight off after stopping popular drugs like Ozempic and semaglutide—something most patients struggle with. In a clinical trial, those who underwent a technique called duodenal mucosal resurfacing regained far less weight compared to others after discontinuing the medication. The procedure works by renewing the lining of the upper small intestine, potentially “resetting” metabolism and preserving the benefits of weight loss.

Facebook

Twitter

FULL STORY

A new gut-based procedure may help people avoid weight regain after stopping Ozempic or semaglutide. By resetting metabolism in the small intestine, it helped patients maintain far more of their weight loss. Credit: Shutterstock

A minimally invasive outpatient procedure may help people avoid regaining weight after stopping popular medications like Ozempic and semaglutide, according to research being presented at Digestive Disease Week® (DDW) 2026. About 70% of people who stop these drugs eventually regain much of the weight they lost, often within 18 months. Nearly one in five adults with obesity has used a glucagon-like peptide-1 (GLP-1), highlighting the scale of this challenge.

Researchers report the first blinded, randomized, sham-controlled evidence that a procedure called duodenal mucosal resurfacing may offer a safe and lasting way to maintain weight loss without ongoing medication. The findings suggest it could help patients hold onto the benefits they achieved while taking drugs such as Ozempic or other GLP-1 therapies.

"As effective as GLP-1 medications are, many people stop taking them because of cost, side effects or simply not wanting to take a drug long-term," said lead author Shelby Sullivan, MD, director of the Endoscopic Bariatric and Metabolic Program at Dartmouth Health Weight Center and professor of medicine, Dartmouth Geisel School of Medicine. "But, if they stop these medications, weight regain occurs in the vast majority of patients, and the metabolic benefits are lost. Finding a treatment that allows patients to stop these medications without weight regain or loss of metabolic benefit is a huge unmet need. These findings indicate that this minimally invasive procedure may provide lasting weight-loss maintenance."

How the "Gut Reset" Procedure Works

Duodenal mucosal resurfacing is an investigational endoscopic treatment that uses controlled heat to remove damaged tissue from the inner lining of the duodenum, the first section of the small intestine just below the stomach. This process, which ablates (burns) the unhealthy mucosal layer, encourages the growth of new, healthier tissue.

The ongoing REMAIN-1 trial is designed to test whether this renewal of the intestinal lining can trigger a lasting metabolic reset, helping the body maintain weight loss after stopping medications like semaglutide or tirzepatide.

Trial Results Show Less Weight Regain

The current findings come from an early group of participants with six months of follow-up data. Among 45 people in this cohort, 29 received the resurfacing treatment while 16 underwent a sham procedure. All participants had previously lost at least 15% of their body weight using tirzepatide before stopping the drug.

On average, patients lost about 40 pounds while on GLP-1 therapy. Six months after discontinuing the medication, those in the control group regained significantly more weight. Participants who received the sham procedure regained about 40% more weight than those who underwent the actual treatment.

In addition, patients who had more extensive resurfacing regained only about 7 pounds and kept more than 80% of their weight loss. By comparison, the control group regained roughly twice as much. The gap between the two groups continued to widen from one to six months after the procedure, suggesting the benefits may persist and even strengthen over time.

"What's particularly encouraging is that the benefit appears to increase over time rather than fade, and that it behaves like a drug in terms of dose response," Dr. Sullivan said. "That gives us confidence that we're targeting the right biology."

Safety and Recovery

No serious complications were reported from either the device or the procedure. Recovery is relatively quick, with most patients returning to normal activities within about a day.

"Other than recovering from the general anesthesia, there isn't much recovery time involved," Dr. Sullivan said. "You can be back to your daily routine in about a day. Participants could not tell if they had the sham or real procedure because there are not a lot of symptoms after the procedure."

Why t